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Transmissible spongiform encephalopa-
thies (TSE) are rare forms of progressive
neurodegenerative disorders that affect both
humans and animals (1). They are distin-
guished by long incubation periods, charac-
teristic spongiform changes associated with
neuronal loss, and a failure to induce
inflammatory response (2). The prototype
TSE in humans, Creutzfeldt-Jakob disease
(CJD), occurs sporadically (approximately
90% of cases), through iatrogenic transmis-
sion of the infective agent (<1% of cases), or
as an autosomal dominant inheritance
(approximately 10% of cases) (3,4). CJD is a
rapidly fatal dementing illness that occurs
worldwide, with an estimated incidence of
approximately one case per million persons.
Unconventional agents termed prion pro-
teins (PrPs), which are encoded by genes on
chromosome 20, are considered the etiologic
agent of CJD. The pathologic properties of
these proteins lie in their three-dimensional
configuration and their ability to recruit and
influence normal PrPs, to undergo similar
conformational changes. The transmissibil-
ity of CJD has been verified with reports of
iatrogenic transmission from a corneal
transplant, electroencephalographic depth
electrodes, neurosurgical procedures, cadav-
eric dura mater grafts, and pituitary
hormone administration (5-11).
A cluster of CJD cases with a unique
neuropathologic picture among unusually
young patients in the United Kingdom (12),
which was reported during a widespread
epizootic of bovine spongiform encephalopa-
thy (BSE), has alerted many countries,
including the United States, to update their
surveillance for CJD and look for similar
cases (13). This increased attention, and the
fact that CJD is rapidly and invariably fatal
(14), prompted us to analyze the most
current CJD deaths and update our analysis
of national trends of CJD mortality in the
United States. Because of concerns about the
theoretical risk for transmission of CJD by
blood transfusion, we also examined the
mortality records for evidence of diseases
associated with increased exposure to blood
or blood products.
Multiple cause-of-death data for the
United States from 1979 through 1994 were
obtained from the National Center for
Health Statistics, Centers for Disease
Control and Prevention (CDC) (15), with
1994 data reported as provisional. Cause-of-
death classifications were based on the
Ninth Revision of the International Classifi-
cation of Diseases (ICD-9) (16-18). CJD
deaths were defined as those for which ICD-
9 code 046.1 appeared as an entity-axis code.
The alternative CJD ICD-9 code 331.5 is not
valid in the United States (17,19,20). The
case of a 3-year-old child with spongiform
degeneration of infancy (ICD-9 code 046.1)
was included in the study. We excluded the
case of a 5-year-old child with Kawasaki
disease (ICD-9 code 446.1) because CJD was
not listed on the death certificate and the
case of a 17-year-old patient who had had
diffuse T-cell proliferative disease.
Creutzfeldt-Jakob Disease in the
United States, 1979-1994: Using National
Mortality Data to Assess the Possible
Occurrence of Variant Cases
After a cluster of Creutzfeldt-Jakob disease (CJD) cases among unusually young
patients was reported recently from the United Kingdom, we examined trends and the
current incidence of CJD in the United States. We found that the age-adjusted CJD
death rate in the United States is similar to published estimates of the crude incidence
of CJD worldwide and has continued to be stable from 1979 through 1994. The
number of CJD deaths in persons <45 years of age remained stable during this period.
We found no evidence of the variant form of CJD.Emerging Infectious Diseases Vol. 2, No. 4—October-December 1996 334
Dispatches
Annual CJD death rates were calculated
as the number of CJD deaths per million
persons, on the basis of U.S. resident
population estimates, and standardized by
the direct method, using the 1990 census
population (21). Age-adjusted annual death
rates were calculated by sex and race and for
the United States overall; age-, sex-, and
race-adjusted annual death rates were
calculated by standard region (22). Risk
ratios (RRs) with 95% confidence intervals
(CIs) were calculated by Poisson regression
analysis (23). Deaths were examined accord-
ing to whether autopsy was indicated on the
death certificate, as available from 1979
through 1993. We also examined other
causes of death listed and  searched the
records for several diseases associated with
increased exposure to blood or blood
products, specifically hemophilia A (ICD-9
code 286.0), hemophilia B (ICD-9 code
286.1), thalassemia (ICD-9 code 282.4), and
sickle cell disease (ICD-9 code 282.6).
From 1979 through 1994, CJD was
recorded as a cause of 3,642 deaths in the
United States; 83.4% of these deaths had
CJD recorded as the underlying cause. The
average annual age-adjusted death rate
during the study period was 0.95 deaths per
million persons, from 0.78 in 1980 to 1.11 in
1987 (Figure 1). The mean age of death was
67 years (median age = 68 years). Approxi-
mately 98% of the deaths were among
persons >45 years of age. The age-specific
death rates were highest for persons in their
70s (Figure 2).
Although 52.9% of the deaths were in
female patients, the age-adjusted death rate
of male patients was slightly higher than
that of female patients (RR = 1.16, 95% CI =
1.09-1.24; Table 1). In contrast to the death
rate in age groups <60 years, the CJD death
rate in age groups >60 years was higher in
men than in women (Table 2). Most (95.2%)
deaths were among whites. The age-adjusted
death rate of whites was higher than that of
blacks (RR = 2.66, 95% CI = 2.22-3.18)
(Table 1). Other races accounted for only
1.4% of the CJD deaths, with an age-adjusted
rate intermediate to that of blacks and
whites. The death rate of blacks was lower
than that of whites in each age group.
Geographically, the age-sex-race-adjusted
rate of the South was lower than that of each
of the other regions. The previously noted
differences by sex and race remained
consistent for each region.
Approximately 80% of the CJD deaths
were among persons >60 years of age. The
average annual death rate during the study
period of this age group was 4.58 per million
persons (3.71 per million in 1983 to 5.52 per
million persons in 1987) (Figure 1). Among
persons 45 through 59 years of age, the
Figure 1. Creutzfeldt-Jakob disease age-adjusted and
age-specific death rates, United States, 1979 through
1994.
Figure 2. Creutzfeldt-Jakob disease deaths and death
rates by age group.  United States, 1979 through 1994.
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sickle cell disease mentioned on the death
record. During 1979 through 1993, autopsies
were performed on 907 persons who died of
CJD-related causes (29.7% of those whose
autopsy status was known). The proportion
of autopsies ranged from 20.7% in 1993 to
37.8% in 1983. Autopsies of persons <45
years of age were indicated in 51.5% of the
known deaths, while 30.2% and 29.0% were
indicated in the 45- to 59-year-old and >60-
year-old age groups, respectively.
During 1979 through 1994, the average
annual age-adjusted death rate was 0.95 per
million persons, which is consistent with
published estimates of the crude incidence
worldwide of one case per million persons
(3,11). The addition of the 4 recent years of
data to our previous report did not alter our
initial findings (24). The previously reported
racial differences in the U.S. CJD death
rates were found again and should be further
studied. In addition, no CJD-related deaths
were found among persons with hemophilia
A, hemophilia B, thalassemia, or sickle cell
disease.
In 1994 and 1995, a cluster of 10
unusually young (median age at onset 28
years, range 16 to 39 years) CJD patients in
the United Kingdom were reported with
atypical clinical features (12). These fea-
tures included behavioral change and dyses-
thesia when patients sought treatment,
followed within weeks or months by a
cerebellar syndrome, dementia, and myoclo-
nus in the late stages, a duration of illness of
at least 6 months, and electroencephalogram
changes that were not diagnostic of CJD.
These patients had a characteristic neuro-
pathologic profile that consisted of severe
spongiform change, neuronal loss, and
astrocytosis in the basal ganglia and
thalamus, with abundant kuru-type amyloid
plaques surrounded by vacuoles in the
cerebrum and cerebellum and PrP accumula-
tion in high density shown by immunocy-
tochemistry. These findings, coupled with
the unusually young age of the patients, led
to the conclusion that the clinicopathologic
features constituted a new variant of CJD. A
causal association with the BSE epizootic in
British cattle was also hypothesized and
recently supported by experimental evidence
involving intracerebral inoculation of cyno-
Table 1: Creutzfeldt-Jakob disease deaths and death
rates in the United States, 1979-1994
Characteristics Number  of Death
   Deaths  Rate
Sexa Male 1714 1.04
Female 1928 0.89
Racea White 3466 1.01
Black   125 0.37
Other     51 0.67
Age group, years
0-4     1 <0.01
5-9     0 0
10-14     0 0
15-19     0 0
20-24     1 <0.01
25-29     3 <0.01
30-34   13 0.04
35-39   23 0.08
40-44   39 0.16
45-49   91 0.45
50-54 183 0.99
55-59 378 2.14
60-64 598 3.55
65-69 765 5.03
70-74 706 5.75
75-79 508 5.60
80-84 225 3.94
85+ 108 2.42
Regionb
Northeast   926 1.06
Midwest 1008 1.04
South 1068 0.83
West   640 0.89
U.S.a 3642 0.95
aAge-adjusted death rates per million persons.
bAge-sex-race-adjusted death rates per million persons.
average annual death rate was 1.15 per
million persons (0.87 to 1.45 per million).
Among persons <45 years of age, the annual
death rate was consistently at or below 0.05
per million persons; the number of deaths
among such young persons was zero in 1984
and eight in 1981 and 1993. Only five
persons who died of CJD during the study
period were younger than 30 years of age,
and in any single year, there was no more
than one such death. In the most recent 5-
year period, 1990-1994, the only person with
CJD in this young age group had received
pituitary-derived human growth hormone.
None of the persons who died of CJD had
hemophilia A, hemophilia B, thalassemia, orEmerging Infectious Diseases Vol. 2, No. 4—October-December 1996 336
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molgus macaques with brain tissue obtained
from cattle with BSE (25).
To help assess the purported uniqueness
and distribution of the newly described CJD
variant, CDC intensified CJD surveillance
activities to seek evidence for the presence of
this variant in the United States (13). In
analyzing the U.S. multiple cause-of-death
data, we did not find any increase in the
number of CJD deaths among persons <45
years of age; also, there were no recent CJD
deaths in persons <30 years of age, except for
the death of the recipient of pituitary-
derived human growth hormone (in contrast,
five of the eight patients originally reported
in the United Kingdom died before the age of
30). To supplement these findings in the
United States, CDC also conducted active
surveillance in its four Emerging Infections
Program sites and in the Metropolitan
Atlanta Active Surveillance Program in
Georgia (total 1993 population 16.3 million)
(13,26); 92% to 100% of neuropathologists
and neurologists were contacted, and infor-
mation was obtained on their patients who
died of CJD from 1991 through 1995. Medical
records and neuropathologic reports of
decedents <55 years of age were also sought
for review. Consistent with national mortal-
ity data, nine (10%) of the case patients were
<55 years of age, only one case patient was
<45 years of age, and no case patient was <30
years of age. Review of clinical and
neuropathologic records of the nine patients
<55 years of age did not show any with the
variant form of CJD.
The validity of multiple cause-of-death
data is potentially a problem because of
possible coding and reporting discrepancies,
including misdiagnoses (24). However, past
reports have indicated that approximately
80% of histologically confirmed CJD patients
were identified through death certificate
searches, using national death registries
(27). Furthermore, the consistency of data
from the active surveillance sites with the
national multiple cause-of-death data sup-
ports the conclusion that annual review of
multiple cause-of-death data provides an
efficient and cost-effective method to moni-
tor CJD incidence (24,27). Active follow-up of
reported CJD deaths in persons <55 years of
age has been initiated in the United States to
improve the national surveillance of poten-
tial cases of the newly described CJD
variant. Access to more current national
mortality data makes this data source even
more beneficial in monitoring CJD deaths in
the United States. Although currently
available CJD surveillance data do not
provide evidence for the variant CJD in the
United States, ongoing CJD surveillance in
this country and elsewhere, especially in the
United Kingdom, will be critical for ulti-
mately determining the geographic distribu-
tion of this illness and its possible
relationship to BSE.
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